Abstract
Multiple myeloma (MM) is an incurable malignancy of plasma cells. The introduction of thalidomide was a milestone in the treatment of MM. Thalidomide analogues termed immunomodulatory drugs (IMiDs) have been developed that are more effective and have less toxicity than thalidomide. The role of lenalidomide in relapsed MM has been well defined. This review discusses the data regarding the upfront use of lenalidomide with dexamethasone or in multidrug combinations, as well as its potential role as maintenance therapy. It also reviews our experience with pomalidomide, a new IMid with remarkable activity in relapsed, refractory MM.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 120-125 |
| Number of pages | 6 |
| Journal | Current Hematologic Malignancy Reports |
| Volume | 6 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 1 2011 |
Keywords
- IMiDs
- Immunomodulatory drugs
- Lenalidomide
- Maintenance therapy
- Multiple myeloma
- Pomalidomide
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research